|Bid||301.40 x 900|
|Ask||302.09 x 1100|
|Day's Range||298.76 - 304.38|
|52 Week Range||234.39 - 387.40|
|Beta (5Y Monthly)||1.31|
|PE Ratio (TTM)||61.40|
|Earnings Date||Aug 04, 2021 - Aug 09, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||374.00|
Abiomed, Inc. ( NASDAQ:ABMD ) saw a decent share price growth in the teens level on the NASDAQGS over the last few...
Abiomed's (ABMD) latest acquisition is expected to improve patient outcome as well as lower the cost of care.
Abiomed (NASDAQ: ABMD) has acquired preCARDIA, developer of a proprietary catheter and controller that will complement Abiomed’s product portfolio to expand options for patients with acute decompensated heart failure (ADHF). The preCARDIA system is uniquely designed to rapidly treat ADHF-related volume overload by effectively reducing cardiac filling pressures and promoting decongestion to improve overall cardiac and renal function.